| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2024-12-24 |
| タイトル |
|
|
タイトル |
Preclinical/clinical trials of thrice-weekly administration of a combination of tegafur/gimeracil/oteracil (TS-1) and toceranib phosphate in dogs with intranasal tumors |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Nishiyama, Yuta
Maruo, Takuya
Fukuyama, Yasuhiro
Odaka, Yuka
Kawata, Eiyu
Ueno, Hirona
Kayanuma, Hideki
Nakayama, Tomohiro
Takahashi, Hiroki
|
| Abstract |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Intranasal tumors in dogs are malignant solid tumors that are primarily treated with radiotherapy and often recur post-treatment. Combination therapy is pivotal in cancer therapy. Effective drugs include fluoropyrimidine 5-fluorouracil (5-FU) and toceranib phosphate. TS-1, an oral formulation containing the 5-FU prodrug tegafur and enzyme modulators gimeracil and oteracil, is proven to be safe in dogs with solid tumors. While the oral drug toceranib phosphate (Palladia®) is safely administered, the combined toxicity with TS-1 is unknown. We aimed to determine the dosage of this combination in dogs. In the preclinical/clinical trials conducted here, we used a standard 3+3 cohort design with fixed doses of toceranib phosphate (2.4 mg/kg) administered thrice weekly. TS-1 administration was initiated at a dose of 0.5 mg/kg (upper limit 2.0 mg/kg) thrice weekly. Four cohorts were included to confirm the safety of TS-1 and toceranib phosphate. Each cohort was followed up for 1 month. The intranasal tumor types included in the clinical trial (n=13) were adenocarcinoma (n=7), squamous cell carcinoma (n=1), non-epithelial malignancy (n=2), undifferentiated carcinoma (n=1), and transitional carcinoma (n=2). The TS-1 dosage could be increased up to its dose limit in the preclinical/clinical trials. The TS-1 dose to combine with toceranib phosphate thrice weekly was 2.0 mg/kg. This regimen was well-tolerated in dogs. Thus, combined TS-1 and toceranib phosphate therapy is safe for dogs with intranasal tumors. |
|
言語 |
en |
| 書誌情報 |
The Journal of veterinary medical science
巻 86,
号 11,
p. 1129-1135,
発行日 2024-11-01
|
| 出版者 |
|
|
出版者 |
The Japanese Society of Veterinary Science |
| DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1292/jvms.23-0455 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 査読 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
査読あり |
86_23-0455.pdf (1.2 MB)
